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Introduction 
Jean-Martin Charcot first distinguished multiple sclerosis (MS) from other neurological 
diseases in 1868 as a pattern of tremors and paralysis in young adults, differing from James 
Parkinson’s description of paralysis agitans in elderly patients1.  Mediated by an autoimmune 
attack against the myelin sheath surrounding axons, the course of MS is both chronic and 
progressive2.  The autoimmune nature of MS was first suggested by early animal studies in 
which self-myelin antigens were used to immunize rodents causing an MS-like disease, later 
termed experimental autoimmune encephalomyelitis (EAE).  EAE is viewed as the major animal 
model for MS, since the two diseases have in common loss of the myelin sheath, accumulation of 
autoreactive T lymphocytes, and production of inflammatory cytokines and chemokines3,4.  
In healthy individuals, the blood brain barrier (BBB) plays a key role in regulating 
leukocyte infiltration into the CNS.  Migration of leukocytes across the vascular endothelium 
during MS and EAE is largely determined by the expression of adhesion molecules and their 
ligands.  Multiple studies have shown that the interaction between two adhesion molecules, α4-
integrin and VCAM-1, is required for the recruitment of inflammatory cells into the CNS 5-7.  
Additional adhesion molecules, including ICAM-1, likely also have significant roles during 
migration.   
The expression of adhesion molecules on the endothelium of the BBB is strongly 
influenced by the presence of inflammatory cytokines.  Tumor necrosis factor α (TNF-α) is one 
cytokine present in MS lesions and is associated with the expression of ICAM-18.   Much 
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attention has also been focused on a second inflammatory cytokine, IL-17.  Like TNF-α, IL-17 
can be detected in inflammatory lesions of MS patients9.  IL-17 is produced by TH17 CD4+ T 
lymphocytes, which are expanded by two other cytokines, IL-6 and transforming growth factor-β 
(TGF-β)10,11.  Co-expression of IL-6 with IL-17 was shown to increase VCAM-1 expression 
during EAE12.  Another well known cytokine, IL-10, is protective during EAE and produced by a 
regulatory population of T lymphocytes.  Regulatory lymphocytes express CD4, CD25, and a 
transcription factor Foxp313, and depletion of this regulatory population of T cells increased the 
severity of EAE14.  These cells are expanded following exposure to TGF-β.   
 Modulation of cytokines can dictate the development of or recovery from MS.  A study 
of MS patients showed that an additional cytokine, macrophage migration inhibitory factor 
(MIF), was elevated in the cerebrospinal fluid (CSF) of patients undergoing a relapse, as well as 
in the CNS of mice following the induction of EAE15,16.  Several MIF knockout studies have 
shown MIF is upstream of the production of TNF-α, IL-1β, and IL-617.  As we have already 
discussed, TNF-α is a critical cytokine for adhesion molecule expression, and IL-6 has an 
important function during the differentiation of TH17 lymphocytes.   
From these studies, we predict the expression of MIF plays a significant role in the 
pathogenesis of EAE and MS.  Part of the difficulty of elucidating new MS therapies has been 
that no single cytokine has been identified which alone can either explain or prevent ongoing 
MS.  Thus, the focus of this project has been to better understand the broader underlying 
mechanisms that lead to neuroinflammation.  The objectives of this project are to determine the 
role of MIF in EAE using genetically deficient mice and to identify potential mechanisms of 
protection.  We will also describe a novel therapeutic inhibitor of MIF. 
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Results 
MIF is required for susceptibility to EAE 
We immunized MIF knockout and wild type control mice with MOG35-55 peptide.  
Knockout mice showed less severe EAE relative to wild type controls (Figure 1).  Furthermore, 
MIF knockout mice also had a lower incidence of EAE, reduced cumulative disease index, and a 
lower peak clinical score relative to controls (Table 1).  Interestingly, the absence of MIF did not 
affect the day of onset, which was similar between groups, or the peripheral response to MOG 
antigen (data not shown).  Previous studies have shown MIF knockout mice are 
immunosuppressed18, so we investigated other mechanisms by which MIF knockout mice could 
be protected. 
 
MIF Knockout Mice Have Reduced Mononuclear Infiltration 
 To evaluate whether MIF was required for leukocyte migration, we measured the 
presence of inflammatory infiltrates in the CNS.  Migration of inflammatory leukocytes into the 
brain and spinal cord is a key factor during EAE and MS.  In wild type mice, there was a 
considerable presence of mononuclear cells surrounding blood vessels in the brain (Figure 2A).  
We found reduced perivascular infiltration in MIF knockout mice and reduced CNS 
inflammation as scored by a pathologist (Figure 2C).  These observations strongly suggested that 
MIF has a role during migration. 
We also examined damage in the brain following immunization. Thirty-five days 
following immunization, damage was assessed by luxol fast blue staining with a silver 
counterstain.  Luxol fast blue measures the presence of myelin, which was reduced in wild type 
mice (Figure 2B).  Wild type mice also developed enhanced axonal severing, appearing as 
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numerous retraction bulbs along axons.  Knockout mice, on the other hand, had much less 
demyelination and axonal severing.  This correlated with reduced clinical severity observed in 
knockout mice.  These data suggest MIF not only facilitates migration into the CNS but also 
subsequent neuronal damage.  Previous reports have shown MIF increases the expression of 
adhesion molecules19.  In MIF knockout mice, reduced expression of adhesion molecules would 
have a profound effect on migration and progression of disease.  However, given the reduced 
damage in the CNS, we predicted other mechanisms of MIF might also mediate inflammation. 
 
MIF Knockout Mice have a Larger Population of Regulatory Cells 
We measured the lymphocyte and antigen presenting cell populations of wild type and 
MIF knockout mice following immunization.  We found no differences in CD4+ or CD8+ T 
lymphocytes and CD19+ B lymphocytes.  Populations of other antigen presenting cells were also 
comparable between groups (data not shown).  A striking difference was the elevation of 
CD25+Foxp3+ lymphocytes in MIF knockout mice (Figure 3A and B).  This population of cells 
can exert regulatory activity through the transcription of Foxp3 and secretion of IL-10.  We 
measured a greater numbers of these cells, plus enhanced production of IL-10 in MIF-deficient 
mice (data not shown).  We concluded from these studies that this population of regulatory cells 
was a mechanism of protection in MIF knockout mice. 
 
A Small Molecule Inhibitor of MIF Reduces Ongoing EAE 
 All studies thus far explored EAE in mice genetically lacking MIF with wild type 
controls.  We investigated whether administration of an inhibitor of MIF after onset of acute 
disease could reduce ongoing EAE.  Through collaboration with Cytokine PharmaSciences, we 
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used two small molecule inhibitors of MIF, CPSI-2705 and CPSI-1306, that disrupt the activity 
of MIF.  Beginning 17 days following immunization with MOG35-55 peptide, we orally 
administered 1.0 mg/kg of CPSI-1306 daily for 21 days.  Mice receiving inhibitor had less severe 
EAE within three days after beginning treatment (Figure 4A).  The CDI during the treatment 
period was lower in those mice receiving inhibitor, and the mean score between groups during 
this period was significantly lower (Table 2).  We concluded that an inhibitor of MIF could be 
therapeutic during ongoing EAE.  We also gave CPSI-1306 at multiple lower doses and found 
that an inhibitor was still therapeutic at 0.01 mg/kg (data not shown). 
 We also assessed the ability of an MIF inhibitor to reduce relapses in a second, relapsing-
remitting model of EAE.  Using SJL mice, we started CPSI-2705, a second MIF inhibitor, 23 
days after immunization for EAE.  This corresponded to the first remission of disease.  We found 
that administration of an inhibitor prevented the onset of a second relapse of disease (Figure 4B).  
Mice receiving inhibitor had less severe clinical disease relative to vehicle treated mice and a 
lower mean clinical score during the treatment period (Table 2).  These results show that MIF 
inhibitors can extend periods of remission and prevent the onset of new relapses. 
 We measured infiltration in the CNS following inhibitor administration.  We found that 
treatment with an MIF inhibitor reduced new infiltration in the brain (Figure 5A).  Using 
immunohistochemistry, we determined macrophages are specifically inhibited from entered the 
CNS (Figure 5B).  We also examined regulatory lymphocyte populations after 21 days of 
inhibitor administration.  As in knockout mice, we found an increased population of 
CD25+Foxp3+ regulatory cells in inhibitor-treated mice (Figure 6A and B).  Together with the 
data gathered in MIF knockout mice, we believe that an inhibitor of MIF inhibits migration and 
may allow the expansion of regulatory T cells. 
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An Inhibitor of MIF is Available in the CNS 
 The efficacy of any pharmaceutical intervention depends not only on the mechanism of 
action of the drug but also its availability at the site of disease.  We evaluated the presence of 
CPSI-2705 in the serum and brain after five days of oral administration.  We found significant 
amounts of inhibitor in both tissues (Figure 7).  However, there was more inhibitor present in the 
brain of mice with EAE than those mice that were healthy controls.  This strongly suggests 
patency of the BBB improves availability of MIF inhibitor in the CNS tissues.  This would 
greatly increase the therapeutic benefit for MS patients, since most drugs cannot typically cross 
the BBB.  Our data shows an MIF inhibitor would be best available at sites of inflammation. 
 
Discussion 
 Autoimmune diseases result from complex processes in which the immune system 
attacks the body, confusing the distinction between self and non-self.  MS is a debilitating 
autoimmune disease that affects nearly 2.5 million individuals worldwide.  Many of the key 
mediators of MS pathogenesis have been actively investigated as therapeutic targets but, at 
present, no single factor such as an individual cytokine or chemokine has been identified which 
alone can slow progression of disease.   Targeting cytokines that mediate multiple mechanisms 
during the inflammatory response represent more focused therapies. 
One such specific cytokine is MIF, a cytokine widely conserved across many species that 
plays a role in balancing inflammation with suppression and regulation of an immune response.  
In order to better understand the role of MIF in the pathogenesis of MS and EAE, we utilized 
mice lacking MIF on a C57Bl/6 background, a mouse strain that is susceptible to EAE and 
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commonly used to model MS.  We found mice lacking MIF are significantly less susceptible to 
EAE induction.  This suggests that MIF plays an important role in influencing susceptibility to 
inflammation.  To better understand how MIF knockout mice were protected, we evaluated the 
degree of migration into the CNS.  We found MIF knockout and inhibitor-treated mice had 
significantly less infiltration. We also noted MIF knockout mice had reduced neuronal damage.  
We predicted the expression of MIF acted through another mechanism, in addition to migration, 
that facilitated inflammation.  We noted both wild type and MIF knockout mice had 
CD4+CD25+Foxp3+ regulatory cells following immunization, but in knockout and inhibitor-
treated mice, these cells were significantly expanded.   
The combination of reduced migration into the CNS and an increased number of Foxp3+ 
regulatory cells in MIF knockout and inhibitor-treated mice are powerful factors mediating 
protection.  We believe the absence of MIF allowed the expansion of regulatory lymphocytes 
and inhibited expression of adhesion molecules, which slowed the progression of EAE.  Past 
studies show MIF increases expression of IL-620.  Co-expression of IL-6 with TGF-β expands 
the TH17 population of cells, a subtype of lymphocytes known to mediate several inflammatory 
diseases.  While driving the expansion of TH17 cells, large production of IL-6 inhibits the 
differentiation of CD4+CD25+Foxp3+ regulatory T cells.  The absence of MIF in knockout mice 
protects this population of regulatory cells.  MIF is also upstream of the production of TNF-α20.  
Both IL-6 and TNF-α activate vascular endothelial cells and cause the surface expression of 
ICAM-1, VCAM-1, and other adhesion molecules.  Without these markers, the incidence and 
severity of EAE is severely reduced.  We believe that the expression of MIF increases production 
of a host of cytokines, each mediating an important aspect of pathogenesis. 
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We have shown that an inhibitor of MIF is therapeutic during EAE.  Two different 
inhibitors, CPSI-1306 and CPSI-2705, reduced ongoing disease severity.  This was marked by 
increases in the number of regulatory T lymphocytes and reduced CNS leukocyte infiltration. 
Any of these could be primary mechanisms in which inhibition of MIF is therapeutic, and all 
could be successful for the management of MS.  Importantly, none of the mechanisms of MIF 
inhibition appear to suppress the immune system.  Rather, MIF is an important mediator of 
several components of the immune response, including autoregulation through regulatory T cells 
and trafficking into the peripheral tissues.  Targeting these multiple components could prove 
most successful for the management of a complicated autoimmune disease like MS. 
 
Materials and Methods 
Mice.  Age-matched C57Bl/6 and SJL mice were purchased from Jackson Laboratories. 
Mouse strains lacking the MIF gene (B6;129S4-Miftm1Dvd) were developed as previously 
described20 and extensively backcrossed onto C57Bl/6 background.  
Induction of Experimental Autoimmune Encephalomyelitis.  For the induction of EAE in 
C57Bl/6 mice, animals were immunized with 200 μg MOG35-55 peptide (Princeton 
Biomolecules) emulsified in complete Freund’s adjuvant (containing 200 μg Mycobacterium 
tuberculosis Jamaica strain), injected intradermally in each of four flanks.  Pertussis toxin (List 
Biological Labs) was injected as an additional adjuvant intraperitoneally (i.p.) on the day of 
immunization and 48 hours later (200 ng in 0.2 ml PBS).  Female SJL mice were immunized 
with 150 μg PLP139-151 peptide (Sigma-Genosys) emulsified in complete Freund’s adjuvant.  
Pertussis toxin was not used for the induction of EAE in SJL mice. 
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All animals were observed daily for EAE clinical signs and scored according to degree of 
paralysis; 0 = no paralysis, 1 = limp tail or ataxia, 2 = limp tail with ataxia, 3 = partial hind limb 
paralysis, 4 = complete hind limb paralysis, and 5 = death.  Cumulative disease index (CDI) was 
calculated as the sum of daily clinical scores from each animal during the course of observation 
and reported as an average within each group.  Peak score was reported as the average maximum 
clinical score within each group over the observed period.  Additional outcome measures 
included EAE incidence and mortality and were calculated based on individual animals reported 
as a mean within each group. 
Flow Cytometry.  Single cell suspensions derived from draining lymph nodes at the sites 
of injection and spleens were stained with anti-CD4 or -CD25 FITC-, PE-, or APC-conjugated 
fluorescent antibodies (BD Biosciences).  Isotype control monoclonal antibodies (BD 
Biosciences) were matched for each fluorochrome.  Cells were labeled at 1 x 106 cells per tube, 
incubated for 30 minutes at 4°C, and processed for intracellular staining.  Cells were 
permeabilized with fix/perm working solution (eBioscience) and stained intracellularly for the 
transcription factor Foxp3 for 30 minutes at 4°C.  Cells were washed twice with permeabilization 
buffer and analyzed using a FACSCalibur flow cytometer.   
Histopathologic Assessment.  Immunohistochemical, hematoxylin and eosin (H&E), 
luxol fast blue with silver contrast, and Bielschowsky silver staining were carried out by The 
Ohio State University Veterinary Sciences core facility.  Brains and spinal cords were removed 
at various time points following immunization and frozen at -80°C in OCT media.  H&E 
sections were graded by a blinded pathologist for mononuclear cell infiltration on a scale of zero 
(no inflammation) to three (diffuse parenchymal infiltration).  Immunohistochemical stains were 
labeled with anti-F4/80 antibodies and evaluated by a blinded pathologist. 
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Drug Administration.  Several small molecule inhibitors of MIF (gift from Cytokine 
PharmaSciences) were administered to mice prior to or following induction of EAE.  Inhibitors 
were given either i.p. or orally (p.o.) for 10 to 21 days.  CPSI-2705 and CPSI-1306 inhibited 
tautomerase assay as previously described21 at concentrations ranging from 1 to 10 μM.  For i.p. 
administration of inhibitors, drug was dissolved in sterile DMSO, and then diluted in PBS for an 
overall ratio of 1:3 (DMSO to PBS).  Orally administered inhibitor was dissolved in 15 percent 
DMSO in 0.1 percent methycellulose in water.  Mice were fed by gavage a total of 50 μl at a 
concentration of inhibitor.  Vehicle controls received 15 percent DMSO in 0.1 percent 
methylcellulose and were included in all experiments.  The time of day of inhibitor 
administration was kept constant, between 1000 h and 1200 h. 
 Inhibitor Assays.  Brains and serum were collected from mice receiving MIF inhibitors 
orally for five days.  To collect serum, mice were anesthetized and blood drawn from the retro-
orbital sinus using heparinized Natelson blood collecting tubes. Samples were centrifuged at 
10,000 g for 15 minutes and collected serum was stored at -20°C.  Analysis of brain 
homogenates and serum was performed by Cytokine PharmaSciences.   
Statistical Analysis.  All statistical references were made based on appropriate methods as 
outlined in the literature22.  Statistical significance between groups for cumulative disease index, 
mean clinical score, and day of onset was calculated using the Students’ t test.  Measures of 
lymphocyte populations, cytokine production, and proliferation also used the t test.  Significance 
for incidence was calculated using a Chi-square.   
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Figure 1:  The genetic deletion of MIF is protective against EAE.  Wild 
type () and MIF knockout () mice were immunized for EAE with 200 μg 
MOG 35-55 peptide in adjuvant.  MIF knockout mice had less severe EAE 
relative to wild-type controls.  Data are representative of four separate 
experiments. 
14.6±2.3
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0.9±1.0** 6.4±8.1**7/13 (54%)**MIF-/- 
2.2±1.3 24.8±18.115/18 (83%)C57Bl/6 
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Table 1: MIF knockout mice have reduced incidence and severity of EAE.  
Wild type and MIF knockout mice were immunized with MOG 35-55 
peptide in adjuvant. 
aDay of onset was calculated as the mean of the first day of clinical scores 
among mice that developed EAE, ±SD. 
bCumulative disease index (CDI) was calculated as the sum of clinical 
scores over the duration of disease per animal and averaged within each 
group, ±SD.   
cPeak score was measured over the duration of disease per animal and 
averaged, ±SD. 
**p<0.01 
11 
01
2
IN
FL
A
M
M
A
TI
O
N
C57Bl/6
MIF-/-*
Figure 2: The absence of MIF prevents infiltration into the CNS.  At 17 
days following immunization with MOG 35-55 peptide, brains were taken 
from wild type and MIF-deficient animals.  (A)  Hematoxylin and eosin 
(H&E) staining of brain sections showed less perivascular infiltration in 
MIF knockout mice versus wild type controls.  (B)  At 35 days post-
immunization, luxol fast blue with silver counterstain revealed more axonal 
degeneration in wild type mice versus MIF knockouts.  (C) Inflammation 
was significantly reduced in MIF-deficient mice, as graded by a blinded 
pathologist (n=5 per group).  Results are representative of three separate 
experiments.   
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Figure 3: Mice lacking MIF have a larger population of regulatory cells 
that are functional.  Lymph nodes from wild type and MIF knockout 
animals were collected 10 days post-immunization. (A and B) Knockout 
mice had an elevation in regulatory CD25+Foxp3+ population of T 
lymphocytes, gated on CD4.  
**p<0.01 
13 
01
2
10 15 20 25 30 35
DAYS POST-IMMUNIZATION
M
EA
N
 C
LI
N
IC
A
L 
SC
O
RE
VEHICLE
CPSI-1306
0
1
2
3
4
10 15 20 25 30 35
DAYS POST-IMMUNIZATION
M
E
AN
 C
LI
NI
C
AL
 S
CO
R
E
VEHICLE
CPSI-2705
A 
B 
Figure 4: A small molecule inhibitor of MIF reduces disease severity in 
two animal models of EAE.  (A) Male C57Bl/6 mice were injected with 
MOG 35-55 peptide and monitored for clinical signs.  At 17 days post-
immunization, mice in the inhibitor-treated group () were fed daily 1.0 
mg/kg CPSI-1306.  Vehicle controls (U) were fed 15 percent DMSO in 0.5 
percent methylcellulose.  Those mice fed inhibitor had reduced severity of 
disease relative to vehicle controls.  (B) Relapsing-remitting EAE was 
induced in female SJL mice with PLP 139-151 peptide.  Following the first 
remission, 23 days post-immunization, mice were given CPSI-2705 ({).  
Vehicle controls were given 15 percent DMSO in 0.5 percent 
methylcellulose ().  Administration of an MIF inhibitor reduced relapses 
and severity of EAE.   
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Table 2: MIF Inhibitor-treated mice have reduced severity of EAE.  
C57Bl/6 mice were immunized with MOG 35-55 peptide and given 
inhibitor beginning 17 days after immunization.  SJL mice were immunized 
with PLP 139-151 peptide and given inhibitor 23 days after immunization.   
aCumulative disease index (CDI) was calculated as the sum of clinical 
scores over the period of treatment per animal and averaged within each 
group, ±SD.   
bMean score was measured over the duration of treatment per animal and 
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Figure 5: An inhibitor of MIF reduced ongoing migration.  Male C57Bl/6 
mice were induced for EAE with MOG 35-55 peptide and monitored for 
clinical signs.  At 17 days post-induction, mice in the inhibitor-treated 
group were fed daily 1.0 mg/kg CPSI-1306.  Vehicle controls were fed a 
dose of 15 percent DMSO in 0.5 percent methylcellulose.  (A) Inhibitor 
treated mice had significantly less infiltration in the brain.  (B)  F4/80+ 
stained macrophages were not identified in inhibitor treated mice. 
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Figure 6: A small molecule inhibitor of MIF expands a regulatory 
population of T lymphocytes.  C57Bl/6 mice were immunized with MOG 
35-55 peptide.  Lymph nodes were collected following administration of 
MIF inhibitor or vehicle control for 21 days.  (A and B) Mice receiving an 
inhibitor of MIF had a larger population of CD25+Foxp3+ lymphocytes, 
gated on CD4.   
**p<0.01 
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Figure 7: A small molecule inhibitor of MIF is present in the brain.  
Following five days of administration of CPSI-2705, blood and brain 
homogenates were collected from mice in which some were immunized for 
EAE with MOG 35-55 peptide.  Inhibitor was present in both the plasma 
and brain of mice (n=4 per group). 
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